mal cysteine protease essential for normal muscle function. 1 It interacts with several proteins, including dysferlin, titin, filamin C, and sarcoplasmic/ endoplasmic calcium-ATPase (SERCA). [2] [3] [4] Calpain-3 plays a role in multiple physiologic and pathophysiologic functions, including muscle regeneration, sarcolemmal repair, sarcomere remodeling, cytoskeleton regulation, and calcium homeostasis. [2] [3] [4] [5] In 1995, CAPN3 recessive mutations were recognized as causative for one of the most common type 2 limb-girdle muscular dystrophies:
LGMD2A. 1, 6 The majority of patients manifested in the first 2 decades of life with proximal lower limb and axial weakness. There was inter-and intrafamilial variability, but patients with 2 null mutations demonstrated a more severe phenotype than those carrying at least 1 missense mutation. 6 Creatine kinase (CK) levels were elevated but normalized in severely weak patients. The mechanism by which CAPN3 mutations lead to weakness remains undefined but seems related to the perturbation of various homeostatic mechanisms, including calcium dysregulation. 7 Recently, Vissing and colleagues reported 10 European families with an autosomal dominant (AD) LGMD co-segregating with an in-frame 21-bp deletion (c.643_663del21, p.Ser215_Gly221del) in CAPN3.
8 Affected individuals had a milder phenotype than those affected by LGMD2A, normal expression of the mutated mRNA, and [CAPN3] loss by Western blot analysis, suggesting a dominant negative effect of the CAPN3 deletion. A critique of the article suggested the alternative possibility of a digenic disease. 9 Although the original authors rebutted the critique, 10 the concept of AD calpainopathy remains controversial. To our knowledge, none of the published subjects with AD calpainopathy underwent extensive molecular testing to search for coexisting mutations in other genes causative of myopathies.
We report the clinical and laboratory findings of 3 unrelated multigenerational families with AD calpainopathy-3 as further support for dominant as well as recessive inheritance of this myopathy.
METHODS
We identified 2 unrelated probands with AD myopathy and another proband with a history suggestive of AD myopathy, all heterozygous for the in-frame 21-bp deletion in CAPN3, c.643_663del21, p.Ser215_Gly221del. Clinical history and findings, CK values, electromyographic (EMG), imaging, and muscle biopsy findings were reviewed. Family history was obtained from the probands and review of available familial medical records. Scrutiny of affected and asymptomatic individual's surnames within the 3 families, who come from different areas of the United States, revealed no overlap or similarity. The study was approved by the institutional review board of the Mayo Clinic, Rochester, Minnesota.
Genetic testing was performed via targeted next generation sequencing (NGS) of 120 genes causative of myopathies or congenital defects of neuromuscular transmission, Sanger sequencing (Invitae, San Francisco, California; PreventionGenetics, Marshfield, Wisconsin; or EGL Genetics, Tucker, Georgia), or whole exome sequencing (WES; Mayo Clinic). WES findings were verified by targeted Sanger sequencing. Briefly, WES was performed on genomic DNA using capture reagent (Agilent SureSelect All Exon V5 Exome; Agilent Technologies, Santa Clara, California) and >95% of the target region was sequenced >203. The coding region of the CAPN3 gene was completely sequenced and the heterozygous c.643_663del21 mutation was detected by 323 at an average read depth of 723.
Three unrelated individuals had Western blot analysis on their muscle biopsies (University of Iowa). Cryosections were cut and pooled from each muscle biopsy, then homogenized before separating proteins on a 3%-13% gradient gel. 11 The antibodies used for Western blotting were Hamlet (anti-dysferlin) and 12A2 (anti-calpain-3), both purchased from Leica Biosystems (Wetzlar, Germany).
RESULTS

Family Descriptions. Family 1 (Norwegian Ancestry).
The proband (IV-16) manifested at age 51 after years of back pain and myalgias. In her mid-60s, she developed a waddling gait and subsequently mild symmetric weakness of the iliopsoas and gluteus medius. Multiple maternal family members were variably affected ( Fig. 1A and Table 1 ).
Family 2 (German Ancestry on Maternal Side and Scandinavian Ancestry on Paternal Side). The proband (V-6) had low back pain, hyperlordosis, and elevated CK in his 20s. He developed proximal limb and abdominal wall muscle weakness in his 40s ( Fig. 2A-C) . Lumbar spine MRI showed paraspinal muscle atrophy (Fig. 2D) . Gluteus medius biopsy revealed mild, chronic myopathic changes (fiber splitting, rare regenerating fibers, mild-tomoderate increase in internalized nuclei, and type 1 fiber predominance). Multiple maternal family members were variably symptomatic (Fig. 1B and Table 1 ).
Family 3 (Mixed Northern European Ancestry).
The proband (II-2) developed myalgias in his mid30s and weakness by his 50s. He had mild proximal weakness and waddling gait at age 57. Lumbar spine MRI revealed fatty replacement of paraspinal FIGURE 1. Pedigrees of family 1 (A), family 2 (B), and family 3 (C). Asterisks denote individuals carrying the CAPN3 mutation. Gray color indicates symptomatic individuals or subjects with elevated CK for whom a neurological evaluation was not available.
muscles. Several family members not available for examination are symptomatic (Fig. 1C) .
Probands in family 1 and 2 had no decrement on 2-HZ repetitive nerve stimulation of the ulnar nerve. With the exception of subject III-10 in family 1, who developed atrial fibrillation in her 80s, affected individuals had no cardiac disease via history and when screened with a 12-lead electrocardiogram and echocardiogram.
Molecular Data and Muscle Western Blot. All 3 probands carried the CAPN3 (c.643_663del21) deletion. Family 1's proband had no additional pathogenic or presumed pathogenic variants (point mutations, deletions, or duplications) on NGS of 120 genes causative of myopathies or congenital defects of neuromuscular transmission that can sometimes be associated with myopathy. Previous genetic testing detected no pathogenic variants in LMNA (laminin A) and CNBP (CCHC-type zinc finger nucleic acid binding protein) in a cousin (IV-13), and there were no pathogenic variants in FKRP (fukutin-related protein), LMNA, CAV3 (caveolin-3), DYSF (dysferlin), SGCA, SGCB, SGCD, SGCG (sarcoglycans alpha, beta, gamma, and delta, respectively), or MYOT (myotilin) in subject III-3. Family 2's proband had no additional pathogenic or suspected pathogenic variants by WES in CAPN3 or in any other gene currently known to cause myopathy or hyperCKemia. Because Starling et al. 12 reported subjects with LGMD carrying a single CAPN3 in-frame deletion associated with a KX gene (X-linked Kx blood group protein) mutation (McLeod syndrome), we also searched for mutations in KX, but found no variants. In addition, the family 1 and family 2 probands had no acanthocytosis, and no subject within the 3 families has chorea. Family 3's proband had no pathogenic variants in genes causative of other LGMD.
Muscle Western blot analysis in the 3 unrelated individuals showed greatly reduced [CAPN3] and normal dysferlin expression (Fig. 2F ).
DISCUSSION
We have described 3 unrelated families of northern European ancestry with AD LGMD due to the c.643_663del21 deletion in CAPN3. These individuals presented with a spectrum of disease severity and weakness affecting predominantly pelvic girdle and axial muscles in mid-adulthood. Back pain and hyperlordosis preceded the reported onset of weakness by years, suggesting early axial involvement. As previously reported by Vissing et al., 9 our patients had a milder phenotype than that commonly observed in recessive calpainopathy, but with phenotypic intrafamilial variability. The abdominal wall muscle weakness, previously recognized as a feature of LGMD2A, was a prominent early clinical finding in family 2's proband, suggesting that this feature also occurs in dominant calpainopathy. Conversely, the early involvement of thigh adductors and hamstrings of LGMD2A 13 was not observed in our patients, who had normal strength in these muscles. Of interest, some patients showed no myopathic EMG changes in clinically weak muscles and minimal muscle histopathologic findings. No patients had lobulated fibers, often observed in LGMD2A. 13 The CK values did not correlate with disease severity, as some affected individuals had normal CK during their clinical course, including family 2's proband.
No additional pathogenic or presumed pathogenic variants were detected in other genes so far known to cause myopathy. In particular, no relevant variants were detected in TTN (titin) DYSF (dysferlin), FLNC (filamin C), and SERCA1, which encode for proteins that interact with [CAPN3] . Therefore, it is unlikely that the loss in [CAPN3] expression detected by Western blot is secondary to another gene so far known to cause myopathy. In addition, muscle biopsies in 3 affected individuals showed no structural abnormalities typical of a specific genetic defect.
[CAPN3] has 4 structural domains and the p.Ser215_Gly221del is in the first domain within a region making many contacts with a loop from the third domain. Although this specific deletion has not been studied in silico, a deletion in this region could theoretically disrupt the interaction between the first and third domains and affect the assembly and activation of the protein. In-silico studies on known point mutations in the first domain have suggested a reduction in the rigidity of this domain and decreased interaction with the third domain, facilitating calpain-3 inactivation.
14 As Vissing et al. 8 postulated, it is possible that the mutated calpain-3 could exert a dominant negative effect. Our study is limited by the lack of objective data for some individuals within each family and a lack of genetic testing of asymptomatic subjects with normal CK levels. We were also unable to test first-order relatives within a family to follow the segregation of the CAPN3 mutation. Despite this, there were enough affected individuals and findings in family 1 and family 2 with complete information to confirm the AD pattern of inheritance of this mutation. and 3) . Although dysferlin appears normal in size and amount for each affected subject, full-length (94-kd) calpain-3 and calpain-3 degradation products are greatly reduced in each subject.
This study has provided further evidence of the pathogenic dominant effect of the CAPN3 c.643_663 in-frame deletion and identified no other potentially pathogenic variants in genes so far known to be causative of myopathies, decreasing the likelihood of digenic disease in individuals harboring this specific mutation.
